MedPath

Thymosin beta-4

Generic Name
Thymosin beta-4
Drug Type
Biotech
CAS Number
77642-24-1
Unique Ingredient Identifier
549LM7U24W
Background

Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.

Clinical Trials
Related News

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Not Applicable
Not yet recruiting
Conditions
Resectable Non-Small-Cell Lung Cancer
Interventions
Drug: Platinum-doublet chemotherapy
First Posted Date
2024-09-23
Last Posted Date
2024-09-23
Lead Sponsor
Xuanwu Hospital, Beijing
Target Recruit Count
40
Registration Number
NCT06607926
Locations
🇨🇳

Xuanwu Hospital, Capital Medical University, Beijing, China

Immuno-effect of Tα1 for Stage I NSCLC

Not Applicable
Recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Yousheng Mao
Target Recruit Count
40
Registration Number
NCT06598839
Locations
🇨🇳

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Thymosin Alpha-1 for irAE Secondary to ICIs

Phase 4
Recruiting
Conditions
IrAE
Interventions
First Posted Date
2023-12-20
Last Posted Date
2023-12-20
Lead Sponsor
Jun Wang
Target Recruit Count
40
Registration Number
NCT06178146
Locations
🇨🇳

The first affiliated hospital of Shandong First Medical University, Jinan, Shandong, China

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Phase 2
Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Radiation: definitive radiotherapy
Drug: induction chemo-immunotherapy
Drug: concurrent chemotherapy
Drug: Immunotheapy consolidation
First Posted Date
2023-11-18
Last Posted Date
2023-11-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
114
Registration Number
NCT06139419
Locations
🇨🇳

Sun yat-sen university cancer center, Guangzhou, Guangdong, China

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Phase 3
Recruiting
Conditions
Neurotrophic Keratopathy
Interventions
Drug: Placebo
First Posted Date
2022-09-27
Last Posted Date
2024-04-19
Lead Sponsor
ReGenTree, LLC
Target Recruit Count
70
Registration Number
NCT05555589
Locations
🇺🇸

Advance Vision Research Institute, Longmont, Colorado, United States

🇺🇸

Washington University Eye Center, Saint Louis, Missouri, United States

🇺🇸

Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons, Danbury, Connecticut, United States

and more 30 locations

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Not Applicable
Conditions
Rheumatic Heart Disease
Immunotherapy
Cardiopulmonary Bypass
Interventions
Other: Blank Control
First Posted Date
2022-08-04
Last Posted Date
2022-08-04
Lead Sponsor
Nanjing Medical University
Target Recruit Count
200
Registration Number
NCT05487469
Locations
🇨🇳

The first affiliated hospital of nanjing medical university, Nanjing, Jiangsu, China

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Phase 3
Recruiting
Conditions
Stage II Colorectal Cancer
Stage III Colorectal Cancer
Interventions
First Posted Date
2021-10-21
Last Posted Date
2021-10-21
Lead Sponsor
Fudan University
Target Recruit Count
2500
Registration Number
NCT05086614
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Long-term Prognosis of Patients With Sepsis After Immunotherapy

Not yet recruiting
Conditions
Long-term Effects of Thymosin Alpha 1 Treatment
Interventions
First Posted Date
2021-05-25
Last Posted Date
2021-05-25
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
900
Registration Number
NCT04901104

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

Phase 4
Conditions
Osteoporotic Pain
Interventions
First Posted Date
2020-08-24
Last Posted Date
2020-08-26
Lead Sponsor
RenJi Hospital
Target Recruit Count
100
Registration Number
NCT04524169
Locations
🇨🇳

Diansan Su, Shanghai, Shanghai, China

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

Phase 3
Conditions
2019 Novel Coronavirus Infection
Interventions
First Posted Date
2020-03-24
Last Posted Date
2020-03-31
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
2944
Registration Number
NCT04320238
Locations
🇨🇳

Taihe Hospital, Shiyan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy